Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

Fulvestrant (Ful) is an effective and widely used agent for first- and second-line treatment of hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2−) metastatic breast cancer (MBC). However, there is no evidence of treatment after progression on Ful. Our study aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yizhao, Zhao, Yannan, Gong, Chengcheng, Chen, Zhanhong, Zhang, Yinbin, Zhao, Yanxia, Yuan, Peng, Hu, Sainan, Li, Yi, Hu, Xichun, Zhang, Jian, Wang, Leiping, Wang, Biyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368624/
https://www.ncbi.nlm.nih.gov/pubmed/30737426
http://dx.doi.org/10.1038/s41598-018-37472-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368624/
https://www.ncbi.nlm.nih.gov/pubmed/30737426
http://dx.doi.org/10.1038/s41598-018-37472-z

Ejemplares similares